Asarfi Hospital Stock Hits All-Time High, Marking a Significant Milestone

On 19 Nov 2025, Asarfi Hospital’s stock touched an intraday high of Rs 218.95, representing a 7.22% increase on the day and closing just 0.76% shy of its 52-week high of Rs 219.95. The stock opened with a gap up of 4.8%, signalling robust demand early in the trading session. Over the last four consecutive days, the stock has delivered a cumulative return of 32.95%, significantly outperforming its sector by 6.29% on the day.

Asarfi Hospital’s market capitalisation is graded at 4, reflecting its mid-cap status within the hospital industry. The stock’s day change of 7.59% stands in stark contrast to the Sensex’s 0.41% movement, emphasising its relative strength in the broader market context. Furthermore, the stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained upward momentum.

Examining the stock’s performance over various time frames reveals a pattern of substantial gains. Over the past year, Asarfi Hospital has generated a return of 154.72%, vastly exceeding the Sensex’s 9.59% return for the same period. Year-to-date, the stock has delivered 119.95% returns compared to the Sensex’s 8.81%. Even over shorter intervals, the stock’s performance remains impressive: a 1-month return of 61.73% versus the Sensex’s 1.27%, and a 3-month return of 74.56% against the Sensex’s 4.13%. These figures illustrate the stock’s ability to outperform the broader market consistently.

Financially, Asarfi Hospital has demonstrated solid results in recent quarters. The company reported its highest quarterly net sales at Rs 44.89 crores, with PBDIT reaching Rs 8.87 crores and PBT less other income at Rs 4.89 crores. Net profit growth of 34.38% was recorded in the September 2025 quarter, marking two consecutive quarters of positive results. These figures contribute to the company’s Mojo Score of 77.0, reflecting an adjustment in its evaluation as of 14 Nov 2025.

From a valuation perspective, Asarfi Hospital presents an enterprise value to capital employed ratio of 3.4, coupled with a return on capital employed (ROCE) of 8.6%. While the ROCE indicates moderate profitability per unit of capital, it remains a key metric in assessing the company’s capital efficiency. The company’s debt servicing capability is underscored by a Debt to EBITDA ratio of 1.44 times, suggesting manageable leverage levels.

Despite the strong recent performance, certain metrics suggest areas of caution. The company’s average ROCE of 8.67% over time points to modest returns on capital employed. Additionally, operating profit growth has averaged 14.76% annually over the past five years, indicating a slower pace of long-term expansion. Institutional investor participation has declined slightly, with a reduction of 1.04% in their stake over the previous quarter, collectively holding 2.24% of the company’s shares. This shift may reflect changing preferences among investors with greater analytical resources.

In summary, Asarfi Hospital’s stock reaching an all-time high is a significant milestone that reflects its recent financial achievements and market performance. The stock’s ability to outperform the Sensex and its sector over multiple time frames, combined with strong quarterly results and manageable debt levels, mark this event as a noteworthy development in the hospital sector.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →